Todd Harris Sells 500 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock

Tyra Biosciences, Inc. (NASDAQ:TYRAGet Free Report) CEO Todd Harris sold 500 shares of the firm’s stock in a transaction dated Monday, September 30th. The stock was sold at an average price of $24.00, for a total transaction of $12,000.00. Following the transaction, the chief executive officer now owns 1,477,373 shares of the company’s stock, valued at approximately $35,456,952. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Todd Harris also recently made the following trade(s):

  • On Wednesday, September 25th, Todd Harris sold 600 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.01, for a total transaction of $14,406.00.
  • On Monday, September 23rd, Todd Harris sold 10,092 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.13, for a total transaction of $243,519.96.
  • On Thursday, September 19th, Todd Harris sold 5,698 shares of Tyra Biosciences stock. The stock was sold at an average price of $24.31, for a total transaction of $138,518.38.

Tyra Biosciences Price Performance

Shares of Tyra Biosciences stock opened at $21.58 on Friday. The firm has a market cap of $1.13 billion, a P/E ratio of -12.85 and a beta of 1.01. The firm has a 50 day simple moving average of $21.75 and a 200 day simple moving average of $18.99. Tyra Biosciences, Inc. has a fifty-two week low of $10.38 and a fifty-two week high of $25.14.

Tyra Biosciences (NASDAQ:TYRAGet Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.09. On average, sell-side analysts expect that Tyra Biosciences, Inc. will post -1.53 EPS for the current year.

Institutional Trading of Tyra Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of TYRA. HighVista Strategies LLC bought a new position in Tyra Biosciences in the second quarter valued at approximately $257,000. SG Americas Securities LLC bought a new position in Tyra Biosciences in the third quarter valued at approximately $311,000. Rhumbline Advisers boosted its stake in Tyra Biosciences by 12.3% in the second quarter. Rhumbline Advisers now owns 23,572 shares of the company’s stock valued at $377,000 after acquiring an additional 2,574 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Tyra Biosciences by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 58,087 shares of the company’s stock valued at $929,000 after acquiring an additional 14,352 shares during the last quarter. Finally, Oppenheimer & Co. Inc. bought a new position in Tyra Biosciences in the first quarter valued at approximately $977,000. Institutional investors and hedge funds own 84.14% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on TYRA shares. Wedbush reaffirmed an “outperform” rating and set a $28.00 price objective on shares of Tyra Biosciences in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $23.00 price objective on shares of Tyra Biosciences in a report on Wednesday, July 3rd. Oppenheimer raised their price objective on shares of Tyra Biosciences from $25.00 to $33.00 and gave the stock an “outperform” rating in a report on Thursday, September 19th. Finally, Piper Sandler began coverage on shares of Tyra Biosciences in a report on Thursday, August 15th. They set an “overweight” rating and a $33.00 price objective for the company. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $26.40.

Read Our Latest Research Report on TYRA

Tyra Biosciences Company Profile

(Get Free Report)

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

Featured Stories

Insider Buying and Selling by Quarter for Tyra Biosciences (NASDAQ:TYRA)

Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.